X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $632.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
The net proceeds from the offering for continued development of its VK2809, a small molecule selective thyroid hormone receptor beta agonist. It is currently being evaluated in a Phase 2b study for for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $550.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
The net proceeds from the proposed offering for continued development of its VK2809, small molecule selective thyroid hormone receptor beta agonist. It is being evaluated in clinical studies for the treatment of non-alcoholic steatohepatitis and fibrosis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2024
Details:
VK2809 novel liver-selective thyroid hormone receptor beta agonist,which is being evaluated for the treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated for biopsy-confirmed non-alcoholic steatohepatitis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated in a Phase 2b clinical trial for biopsy-confirmed non-alcoholic steatohepatitis.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) will be presented at the Digital International Liver Congress™ 2020.
Lead Product(s): VK2809
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VK2089
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
